Artiva Biotherapeutics, Inc.

NasdaqGM:ARTV Stock Report

Market Cap: US$333.8m

Artiva Biotherapeutics Future Growth

Future criteria checks 0/6

Artiva Biotherapeutics's earnings are forecast to decline at 6.5% per annum while its annual revenue is expected to grow at 81.8% per year. EPS is expected to grow by 12.5% per annum.

Key information

-6.5%

Earnings growth rate

12.49%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth rate81.8%
Future return on equityn/a
Analyst coverage

Good

Last updated25 May 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • May 08

Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA

Summary Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus rituximab in refractory RA. Company's AlloNK plus rituximab demonstrated strong ACR50 response rates in early studies, with phase 3 initiation targeted for 2H 2026 and data expected in 2H 2028. The company addresses a significant unmet need in 3rd-line RA, targeting 150K–200K U.S. patients unresponsive to prior biologics, with a $5 billion spend on this population. Recent $300M capital raise extends runway beyond Q2 2027, supporting late-stage trials and pipeline expansion into other B-cell-mediated autoimmune disorders. Read the full article on Seeking Alpha
Analysis Article • Jul 09

We Think Artiva Biotherapeutics (NASDAQ:ARTV) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 20

Will Artiva Biotherapeutics (NASDAQ:ARTV) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jul 22

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Summary Artiva Biotherapeutics, Inc. debuts on NASDAQ with a $167 million IPO, expected to close on July 22, 2024. AlloNK therapy aims to enhance efficacy of B-cell depleting monoclonal antibodies for autoimmune disorders and cancers. Initial data from either investigator trial or phase 1/1b study using AlloNK + rituximab combination for treatment of patients with SLE/LN/autoimmune disorders, expected in the 1st half of 2025. The global market for systemic lupus erythematosus and lupus nephritis is estimated to reach $4.2 billion by 2031. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGM:ARTV - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-173-151-1505
12/31/2027N/A-136-121-1186
12/31/2026N/A-102-90-936
3/31/2026N/A-87-80-78N/A
12/31/2025N/A-84-79-77N/A
9/30/2025N/A-79-79-77N/A
6/30/2025N/A-75-71-69N/A
3/31/2025N/A-72-61-60N/A
12/31/20240-65-56-55N/A
9/30/20243-61-52-51N/A
6/30/202429-33-51-50N/A
3/31/202433-26-50-48N/A
12/31/202333-29-51-47N/A
3/31/20235-63-63-55N/A
12/31/20225-59-57-51N/A
3/31/20223-41-36-33N/A
12/31/20212-72-17-15N/A
9/30/20211-66-13-12N/A
12/31/2020N/A-18-14-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARTV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARTV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARTV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARTV is forecast to have no revenue next year.

High Growth Revenue: ARTV is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ARTV's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/03 07:05
End of Day Share Price 2026/06/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Artiva Biotherapeutics, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Edward WhiteH.C. Wainwright & Co.
Emily BodnarH.C. Wainwright & Co.